| 2.52 Real-Time Quote |  -0.025 / -0.98%Today’s Change | 1.51 Today|||52-Week Range 4.00 | +30.99% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $133.9M |
Company Description
ImmunoCellular Therapeutics Ltd. is a clinical-stage biotechnology company, which focuses on developing new immune-based products to treat and diagnose cancer. Its cell-based vaccine technologies are primary platform technologies and commercial prospects will be heavily dependent on the outcome of the contemplated clinical trials for current lead vaccine product candidate. Its product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular product candidates include ICT-107, CT-121, ICT-109, ICT-037, ICT-69 and CT-Diagnostic-SCLC. The company main disease focuses using its immunotherapy technologies is to treat glioblastoma, and also these therapies applicable to multiple other cancers such as pancreatic, colon and breast cancers due to presence of similar epitopes on these malignant cells. Its antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer. The company was founded on March 20, 1987 and is headquartered in Woodland Hills, CA.
Employees
Shareholders
| Other institutional | 7.49% |
| Mutual fund holders | 5.55% |
| Individual stakeholders | 1.91% |
Top Executives
| John S. Yu, MD | Chairman & Chief Scientific Officer |
| Andrew Gengos, MBA | President, Chief Executive Officer & Director |
| David E. Fractor, CPA | CFO, Treasurer & Chief Accounting Officer |
| James G. Bender, PhD | Vice President-Product Development & Manufacturing |
| Peter Ho, PhD, MBA | Head-Business Development & Licensing |
.
